[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.183.113. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 11, 2002

Risks of Postmenopausal Hormone Replacement

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(22):2822. doi:10.1001/jama.288.22.2822-JLT1211-1-10

To the Editor: In the WHI trial,1 clinic gynecologists were unblinded to treatment assignment for 41% of women in the estrogen plus progestin group and 7% of women in the placebo group. It is thus uncertain whether the study succeeded in maintaining blinding of other clinical staff to prevent detection bias. Such potential for detection bias is of less concern for more objective clinical outcomes such as stroke, but could be of concern for more uncertain outcomes such as venous thromboembolism. Despite defined algorithms and central training, agreement rates between local and central adjudication were only 84% for MI and 84% for deep venous thrombosis, suggesting that outcome adjudication may not have been independent of treatment assignment.

×